Drug intelligence / Profile preview

Qutanling Inhalation Solution

Development stage: Preclinical
Lead developer: Beijing Yingkerei Pharmaceutical Technology
Modality: Small Molecules
Administration: Inhalation

Overview

Qutanling Inhalation Solution (吸入用祛痰灵溶液) is a traditional Chinese medicine (TCM) candidate developed by Beijing Yingkerei Pharmaceutical Technology for the treatment of respiratory diseases. Formulated for delivery via nebulization, the drug is designed to facilitate expectoration and clear respiratory secretions. As a modernized TCM product, it aims to provide targeted therapeutic effects in the lungs while minimizing systemic exposure. The drug is currently in the preclinical stage of development and is part of Yingkerei's specialized pipeline of inhaled TCM therapies.

Other names: 吸入用祛痰灵溶液Qutanling祛痰灵

Beyond the preview

Go deeper on Qutanling Inhalation Solution.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qutanling Inhalation Solution.

Explore the full profile